Integrum Q1 - Miss on sales
2025-09-02 10:33:00
Redeye argues that the relatively disappointing quarterly figures increase the likelihood of the shareholders accepting the SEK44 bid offer. The two remaining weeks of the acceptance period offer investors a compelling IRR
Read more and download the Research Update.
Follow companies at Redeye to receive the latest equity research within Life Science and Technology.
This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/